Patients must have lactate dehydrogenase (LDH) obtained within 28 days prior to registration in order to obtain baseline stratification information
Serum lactate dehydrogenase (LDH) < 10 X ULN (patients with LDH > 10 X ULN are felt to have aggressive disease and should be considered for BRAF inhibitor therapy off protocol), obtained within 4 weeks prior to randomization
Patients must have the following components of Follicular Lymphoma International Prognostic Index (FLIPI) available from diagnosis, and collected again at time of registration:\r\n* Age\r\n* Lactate dehydrogenase (LDH)\r\n* Number of nodal groups involved\r\n* Serum or plasma hemoglobin \r\n* Ann Arbor stage\r\nAdditionally, patients must have beta-2-microglobulin collected at time of registration
Patients must have lactate dehydrogenase (LDH) performed within 28 days prior to registration
Within 10 (except as noted) days of planned treatment initiation: Lactate dehydrogenase (LDH) =< 1.5 x institutional ULN (may be within 28 days)
Baseline labs as within standard of care (complete blood count [CBC], comprehensive metabolic panel [CMP], lactate dehydrogenase [LDH], erythrocyte sedimentation rate [ESR], etc) are required within 14 days of enrollment
Lactate dehydrogenase (LDH) =< 1.5 x ULN
Patients with symptomatic leukemic meningitis, bony or gastrointestinal (GI) tract involvement, serum calcium or lactate dehydrogenase (LDH) > 1.5 X the upper limit of normal will be excluded; however, patients that have both ATL and another HTLV-1 associated disease such as tropical spastic paraparesis (HTLV-I-associated myelopathy [HAM]/tropical spastic paraparesis [TSP]) will be included
Subjects must have serum lactate dehydrogenase (LDH) > institutional upper limit of normal (ULN) at time of study enrollment
LDH < 2 times ULN for each institution.
Serum lactate dehydrogenase (LDH) level =< 1.5 upper limit of normal (ULN) within 28 days prior to enrollment
Serum lactate dehydrogenase (LDH) levels < 1.5 × ULN
LDH ?2.5 times the ULN.
Serum lactate dehydrogenase (LDH) not greater than 1.5 times the upper limit of the local laboratory assay within 14 days of RPLND
LDH < 2 x ULN
Normal serum lactate dehydrogenase (LDH)
Lactate dehydrogenase (LDH) - no clinically significant findings
Serum lactate dehydrogenase (LDH) > 1.5 x institutional ULN
At least one risk factor predicting higher likelihood of bone marrow sample yield: elevated alkaline phosphatase, low hemoglobin, or elevated lactate dehydrogenase (LDH)
Melanoma patients with an LDH ? 3 x ULN.
Serum lactate dehydrogenase (LDH) =< 10 X ULN
Lactate dehydrogenase (LDH) < 5 × upper limits of normal\r\n* (NOTE: these criteria will select against patients with bulky disease and will select for patients with less disease and earlier disease)
Patient with group classification A disease, or group classification B stage I or II disease with normal lactate dehydrogenase (LDH) level AND tumor mass less than 7 cm; NOTE: Patients who would be excluded from treatment on this protocol strictly for laboratory or performance status abnormalities can be included at the principal investigator’s discretion after consultation with the members of the Texas Children's Hospital (TXCH) Lymphoma Team
Current or prior features of acute (corrected calcium [Ca]++ > 2.73 or lactate dehydrogenase [LDH] > 2-fold above ULN) or chronic (LDH 1.5-2-fold above ULN or absolute lymphocyte count > 4 x 10^9/L with T-cells > 3.5 x 10^9/L) ATL; patients with smoldering ATL (no acute or chronic features) and symptomatic ATL skin lesions are also eligible
The following tests must be performed within 42 days prior to registration either for diagnosis/staging or to obtain baseline values:\r\n* White blood cells (WBC)\r\n* Hemoglobin\r\n* Lactate dehydrogenase (LDH)\r\n* Hepatitis B-surface antigen (Ag) and anti-core antibody (Ab)
Patients must have lactate dehydrogenase (LDH) performed within 42 days prior to registration
Subject must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and must have a serum lactate dehydrogenase (LDH) ? 1.0 X upper limit of normal and adequate hematologic, hepatic, renal, and coagulation organ function- Other criteria may apply
LDH level ? 1.5 × ULN at screening
LDH level ? 1.5 × ULN at screening.
Within 4 weeks of administration of study therapy: Lactate dehydrogenase (LDH) < 4 x upper limit of normal (ULN)
Patients with melanoma must have a serum lactate dehydrogenase (LDH) test performed within 28 days prior to registration
Stage III with elevated LDH level (\B-high\), [LDH > twice the institutional upper limit of the adult normal values (> Nx2)] or any stage IV or B-AL.
Meets criteria for poor-risk defined as 3 or more of the following: ECOG performance status 2, anemia (hemoglobin lower than reference range), elevated serum lactate dehydrogenase (LDH) > 1.5 x upper limit of normal (ULN), hypercalcemia (corrected serum calcium level > upper limit of normal), time from initial RCC diagnosis to registration on this trial < 1 year, and > 1 metastatic organ sites
Lactate dehydrogenase (LDH) within normal limits (WNL)
Elevated lactate dehydrogenase (any elevation above normal range)
Sufficient data to calculate the International Prognostic Index (IPI) score at baseline:\r\n* Age\r\n* Stage of disease\r\n* Lactate dehydrogenase (LDH)\r\n* ECOG performance status\r\n* Number of extranodal sites
increase in serum Lactase Dehydrogenase (LDH)
Subject has a known elevation in serum lactate at screening ? 2x institutional ULN
LDH < 1.50 X institutional upper limit of normal
Lactate dehydrogenase (LDH) ? 2 times the upper limit of normal (ULN).
Lactate dehydrogenase (LDH): there is no restriction
Patients must have lactate dehydrogenase (LDH) obtained prior to registration
Lactate dehydrogenase < 2 x ULN
Lactate dehydrogenase (LDH) less than 4.0 times below or above the upper or lower limit range
Lactate dehydrogenase (LDH) less than 4.0 times below or above the upper or lower limit range
LDH ?2.0 times the ULN range of each institution
Elevated LDH levels are permissible if transaminases are =< IULN